Zentalis Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Zentalis Pharmaceuticals announced that its management team will participate in two investor conferences in November 2026.
Stocks · News reference
Zentalis Pharmaceuticals Announces Inducement Grants for New Employees
Zentalis Pharmaceuticals, Inc. granted non-qualified stock options to four newly hired employees as an inducement for their employment.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted non-qualified stock options to purchase 136,000 shares to four newly hired employees on November 2, 2026, with an exercise price of $1.85 per share. The options vest over four years under the company's 2022 Inducement Plan.
Mizuho Securities Lowers Price Target for Zentalis Pharmaceuticals
Mizuho Securities has adjusted its price target for Zentalis Pharmaceuticals, Inc., lowering it from $8 to $7.
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
Zentalis Pharmaceuticals announced interim overall survival data from the DENALI Part 1b study of azenosertib, its investigational WEE1 inhibitor for platinum-resistant ovarian cancer. In Cyclin E1-positive patients (n=48), median OS was 15.8 months compared to 7.5 months in Cyclin E1-negative patients (n=46). The company concluded that Cyclin E1 is a highly selective biomarker for azenosertib response, with OS data comparing favorably to historical chemotherapy benchmarks, supporting continued development in Phase 3 trials.
HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy and maintains $10 price target.
Zentalis, On Sunday, Announced Interim DENALI Part 1b Data Showing Median Overall Survival Of 15.8 Months With Azenosertib Monotherapy In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer